Learning from remission and relapse in lupus (SLE)
Official title: Learning from Remission and Relapse in SLE
Funded at Feinstein Institute for Medical Research · NIH-11513534 · Data updated 2026-11-12
Researchers are studying people with systemic lupus erythematosus who are in long-term remission without steroids or immunosuppressants to understand their immune cells, brain function, and what might predict relapse.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Feinstein Institute for Medical Research NIH-funded |
| Lab location | 1 site (Manhasset, United States) |
| Project start | May 9, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $83,448 |
| NIH project number | 3P01AI172523-03S2 |
| Project ID | NIH-11513534 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Systemic Lupus Erythematosus in long-term remission off corticosteroids and immunosuppressants.
✕Less likely to help
Patients who are not in lupus remission or who require ongoing immune-suppressing therapy may not benefit from this study.
What this research studies
This project looks at immune cells in blood at the single-cell level to map cell types, gene activity, and protein patterns. It also examines B cell receptors that react to nuclear components and uses brain assessments to see if there is quiet inflammation in the brain even when the body seems calm. The goal is to find links between immune profiles and brain activity, and to identify factors that predict relapse within five years. By capturing patient diversity and potential new states of immune-brain balance, the study aims to guide future care for people with lupus.
Why it matters
Potential benefit: If successful, the work could help predict who is at risk of relapse and inform personalized strategies to maintain remission.
How similar studies have gone: This line of inquiry has shown that immune and brain states can relate to disease activity, but this specific remission-relapse profiling is relatively novel.
Where this research is happening
-
Feinstein Institute for Medical Research
Manhasset, United States Active
Researchers
- Principal investigator: Diamond, Betty — Feinstein Institute for Medical Research
- Study coordinator: Diamond, Betty
Related research
Other NIH-funded projects on the same topics.
-
Social stress and smoking: why disadvantaged young adults struggle to quit
This grant looks at how daily social stress affects if and when disadvantaged young adults who smoke can quit and stay quit.
-
Learning from Remission and Relapse in SLE
A program to study people with systemic lupus erythematosus who are in long-term remission to understand immune and brain signals that might predict relapse.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Predictors of autoimmunity onset and relapse in skin
A study to understand what biological signals in skin predict when autoimmune diseases start, flare, or worsen in people at risk.
-
Determinants of TB Control, Relapse, and Reinfection
A large, multi-year study aims to understand why some people who are treated for TB still have persistent infection or relapse, with the goal of improving prevention and treatment.
-
Metabolic drivers of B-ALL diversity and relapse risk
A study at Stanford will explore how diverse B-cell receptor rearrangements and their metabolism shape relapse risk in children and adults with B-ALL, with the goal of improving detection and treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.